title: Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.
abstract: The long-term follow-up (greater than or equal to 4 years) of clinical, hormonal and radiological aspects in 22 'cured' prolactinoma patients after adenomectomy was studied. Dynamic secretion of PRL and TSH was also evaluated, in order to identify the persistence of any underlying abnormality of hypothalamic pituitary control and to predict relapses. A relapse into hyperprolactinaemia was shown in 36% of patients 5-90 months (mean 46) after surgery. This was accompanied by reappearance of clinical symptoms but not by the radiological demonstration of the adenoma in any patients. A significant PRL rise after domperidone, a dopaminergic antagonist drug, was shown in cured patients after surgery (mean +/- SEM peak, 2977 +/- 645 mU/l) but this was markedly lower than that observed in control subjects (5732 +/- 440 mU/l). In fact, normal PRL increments were shown in only 6/16 (37%) patients. TSH hyper-responsiveness to domperidone normalized in only 46% of patients. Similar PRL responses to those obtained with domperidone were shown when a TRH test was given. A relapse into hyperprolactinaemia was observed in six of ten (60%) non-responders to domperidone and in four of seven (57%) non-responders to TRH, whereas six normal responders to domperidone and TRH had not relapsed at that time. Plasma PRL levels during pregnancy showed increments lower than those observed in normal pregnant women only in domperidone and TRH non-responder patients. These results indicate that a relapse into hyperprolactinaemia and a blunted PRL rise during pregnancy were present only in patients with persistently reduced PRL response to dynamic tests.
authors.affiliation: Department of Biomedicine, University of Turin, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ciccarelli
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
authors.forename: C
authors.initials: C
authors.lastname: Miola
authors.forename: G
authors.initials: G
authors.lastname: Gandini
authors.forename: E E
authors.initials: EE
authors.lastname: Muller
authors.forename: F
authors.initials: F
authors.lastname: Camanni
mesh_terms: D000236:Adenoma / Q000601:surgery; D000315:Adrenalectomy; D000328:Adult; D004294:Domperidone / Q000627:therapeutic use; D018492:Dopamine Antagonists; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010911:Pituitary Neoplasms / Q000473:pathology / Q000601:surgery*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000473:pathology / Q000601:surgery*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
chemical_list: D018492:Dopamine Antagonists; D004294:Domperidone; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013972:Thyrotropin